Sensei Biotherapeutics, Inc. (FTH) – What Are Investment Firms Saying About This Stock?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) has earned an average rating of “Buy” from the seventeen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twelve have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $56.25.

Several analysts recently issued reports on FTH shares. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a report on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Oppenheimer assumed coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target on the stock. William Blair began coverage on shares of Sensei Biotherapeutics in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th.

Sensei Biotherapeutics Stock Performance

FTH stock opened at $17.08 on Tuesday. The firm’s 50-day moving average price is $30.37. The stock has a market capitalization of $441.35 million, a P/E ratio of -0.12 and a beta of -0.29. Sensei Biotherapeutics has a 12-month low of $7.45 and a 12-month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Equities analysts predict that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at $307,000. Renaissance Technologies LLC boosted its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. Bank of America Corp DE raised its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.